{"id":"https://openalex.org/W2285196165","doi":"https://doi.org/10.1158/1535-7163.mct-15-0617","title":"A Novel RAF Kinase Inhibitor with DFG-Out\u2013Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation","display_name":"A Novel RAF Kinase Inhibitor with DFG-Out\u2013Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation","alternate_titles":[],"publication_year":2016,"publication_date":"2016-03-01","ids":{"openalex":"https://openalex.org/W2285196165","doi":"https://doi.org/10.1158/1535-7163.mct-15-0617","mag":"2285196165","pmid":"https://pubmed.ncbi.nlm.nih.gov/26916115"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-15-0617","doi":"https://doi.org/10.1158/1535-7163.mct-15-0617","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-15-0617","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2285196165"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023344154","display_name":"Irene C. Waizenegger","orcid":"https://orcid.org/0000-0002-3911-6970","observed_orcids":["https://orcid.org/0000-0002-3911-6970"]},"institutions":[{"id":"https://openalex.org/I4210119669","display_name":"Boehringer Ingelheim (Austria)","ror":"https://ror.org/026vtvm28","country_code":"AT","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210119669"]}],"countries":["AT"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Irene C. Waizenegger","raw_affiliation_strings":["1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria","institution_ids":["https://openalex.org/I4210119669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003811693","display_name":"Anke Baum","orcid":"https://orcid.org/0000-0001-8083-4416","observed_orcids":["https://orcid.org/0000-0001-8083-4416"]},"institutions":[{"id":"https://openalex.org/I4210119669","display_name":"Boehringer Ingelheim (Austria)","ror":"https://ror.org/026vtvm28","country_code":"AT","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210119669"]}],"countries":["AT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Anke Baum","raw_affiliation_strings":["1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria","institution_ids":["https://openalex.org/I4210119669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067049836","display_name":"Steffen Steurer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119669","display_name":"Boehringer Ingelheim (Austria)","ror":"https://ror.org/026vtvm28","country_code":"AT","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210119669"]}],"countries":["AT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Steffen Steurer","raw_affiliation_strings":["2Department of Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria","institution_ids":["https://openalex.org/I4210119669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008716956","display_name":"Heinz Stadtm\u00fcller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119669","display_name":"Boehringer Ingelheim (Austria)","ror":"https://ror.org/026vtvm28","country_code":"AT","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210119669"]}],"countries":["AT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Heinz Stadtm\u00fcller","raw_affiliation_strings":["2Department of Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria","institution_ids":["https://openalex.org/I4210119669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055761451","display_name":"Gerd Bader","orcid":"https://orcid.org/0000-0002-8410-3415","observed_orcids":["https://orcid.org/0000-0002-8410-3415"]},"institutions":[{"id":"https://openalex.org/I4210119669","display_name":"Boehringer Ingelheim (Austria)","ror":"https://ror.org/026vtvm28","country_code":"AT","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210119669"]}],"countries":["AT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gerd Bader","raw_affiliation_strings":["2Department of Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria","institution_ids":["https://openalex.org/I4210119669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079211488","display_name":"Otmar Schaaf","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119669","display_name":"Boehringer Ingelheim (Austria)","ror":"https://ror.org/026vtvm28","country_code":"AT","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210119669"]}],"countries":["AT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Otmar Schaaf","raw_affiliation_strings":["3Department of Discovery ADME, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Department of Discovery ADME, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria","institution_ids":["https://openalex.org/I4210119669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011186689","display_name":"Pilar Garin\u2010Chesa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119669","display_name":"Boehringer Ingelheim (Austria)","ror":"https://ror.org/026vtvm28","country_code":"AT","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210119669"]}],"countries":["AT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Pilar Garin-Chesa","raw_affiliation_strings":["1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria","institution_ids":["https://openalex.org/I4210119669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049049817","display_name":"Andreas Schlattl","orcid":"https://orcid.org/0009-0008-1357-355X","observed_orcids":["https://orcid.org/0009-0008-1357-355X"]},"institutions":[{"id":"https://openalex.org/I4210119669","display_name":"Boehringer Ingelheim (Austria)","ror":"https://ror.org/026vtvm28","country_code":"AT","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210119669"]}],"countries":["AT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andreas Schlattl","raw_affiliation_strings":["1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria","institution_ids":["https://openalex.org/I4210119669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080902591","display_name":"Norbert Schweifer","orcid":"https://orcid.org/0000-0002-0458-1792","observed_orcids":["https://orcid.org/0000-0002-0458-1792"]},"institutions":[{"id":"https://openalex.org/I4210119669","display_name":"Boehringer Ingelheim (Austria)","ror":"https://ror.org/026vtvm28","country_code":"AT","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210119669"]}],"countries":["AT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Norbert Schweifer","raw_affiliation_strings":["1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria","institution_ids":["https://openalex.org/I4210119669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076653808","display_name":"Christian Haslinger","orcid":"https://orcid.org/0000-0002-9924-2231","observed_orcids":["https://orcid.org/0000-0002-9924-2231"]},"institutions":[{"id":"https://openalex.org/I4210119669","display_name":"Boehringer Ingelheim (Austria)","ror":"https://ror.org/026vtvm28","country_code":"AT","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210119669"]}],"countries":["AT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Christian Haslinger","raw_affiliation_strings":["1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria","institution_ids":["https://openalex.org/I4210119669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034579385","display_name":"Florian Colbatzky","orcid":"https://orcid.org/0000-0001-8987-1619","observed_orcids":["https://orcid.org/0000-0001-8987-1619"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Florian Colbatzky","raw_affiliation_strings":["4Department of Non-clinical Drug Safety, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Non-clinical Drug Safety, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055489519","display_name":"Sien Mousa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sien Mousa","raw_affiliation_strings":["4Department of Non-clinical Drug Safety, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Non-clinical Drug Safety, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034505738","display_name":"Arno Kalkuhl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Arno Kalkuhl","raw_affiliation_strings":["4Department of Non-clinical Drug Safety, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Department of Non-clinical Drug Safety, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056562930","display_name":"Norbert Kraut","orcid":"https://orcid.org/0000-0003-3941-7105","observed_orcids":["https://orcid.org/0000-0003-3941-7105"]},"institutions":[{"id":"https://openalex.org/I4210119669","display_name":"Boehringer Ingelheim (Austria)","ror":"https://ror.org/026vtvm28","country_code":"AT","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210119669"]}],"countries":["AT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Norbert Kraut","raw_affiliation_strings":["1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria","institution_ids":["https://openalex.org/I4210119669"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5114250394","display_name":"G\u00fcnther R. Adolf","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119669","display_name":"Boehringer Ingelheim (Austria)","ror":"https://ror.org/026vtvm28","country_code":"AT","type":"company","lineage":["https://openalex.org/I1330995197","https://openalex.org/I4210119669"]}],"countries":["AT"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"G\u00fcnther R. Adolf","raw_affiliation_strings":["1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Pharmacology and Translational Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria","institution_ids":["https://openalex.org/I4210119669"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5023344154"],"corresponding_institution_ids":["https://openalex.org/I4210119669"],"apc_list":null,"apc_paid":null,"fwci":1.9369,"has_fulltext":false,"cited_by_count":101,"citation_normalized_percentile":{"value":0.86436808,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"15","issue":"3","first_page":"354","last_page":"365"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/raf-kinase-inhibitors","display_name":"Raf kinase inhibitor","score":0.9459999799728394},{"id":"https://openalex.org/keywords/dfg-out-conformation","display_name":"DFG-out conformation","score":0.8569999933242798},{"id":"https://openalex.org/keywords/braf-mutant-melanoma","display_name":"BRAF-mutant melanoma","score":0.9120000004768372},{"id":"https://openalex.org/keywords/vemurafenib","display_name":"vemurafenib","score":0.9150000214576721},{"id":"https://openalex.org/keywords/trametinib","display_name":"trametinib","score":0.800000011920929},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.8230000138282776},{"id":"https://openalex.org/keywords/vemurafenib-resistance","display_name":"vemurafenib resistance","score":0.8629999756813049},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8320000171661377},{"id":"https://openalex.org/keywords/therapeutic-window","display_name":"therapeutic window","score":0.6639999747276306},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.6899999976158142},{"id":"https://openalex.org/keywords/toxicity","display_name":"toxicity","score":0.4519999921321869}],"concepts":[{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.9264752268791199},{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.8871784806251526},{"id":"https://openalex.org/C2778830669","wikidata":"https://www.wikidata.org/wiki/Q3011604","display_name":"Dabrafenib","level":5,"score":0.7671923637390137},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.6401076316833496},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5858628749847412},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5285531282424927},{"id":"https://openalex.org/C194409129","wikidata":"https://www.wikidata.org/wiki/Q103824","display_name":"Hematology","level":2,"score":0.5186435580253601},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.46135756373405457},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.4573199152946472},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.4393540620803833},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3963627219200134},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3400431275367737},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.1536557674407959},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.08746302127838135},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08313068747520447}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004789","descriptor_name":"Enzyme Activation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007527","descriptor_name":"Isoenzymes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008958","descriptor_name":"Models, Molecular","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008968","descriptor_name":"Molecular Conformation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D015394","descriptor_name":"Molecular Structure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055503","descriptor_name":"Protein Multimerization","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.mct-15-0617","doi":"https://doi.org/10.1158/1535-7163.mct-15-0617","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-15-0617","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:26916115","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26916115","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:dora:psi_5696","doi":null,"is_oa":false,"landing_page_url":"https://www.dora.lib4ri.ch/psi/item/psi:5696","pdf_url":null,"source":{"id":"https://openalex.org/S4306402574","display_name":"DORA PSI (Paul Scherrer Institute)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2802229908","host_organization_name":"Paul Scherrer Institute","host_organization_lineage":["https://openalex.org/I2802229908"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320320879","display_name":"Deutsche Forschungsgemeinschaft","ror":"https://ror.org/018mejw64"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":38,"referenced_works":["https://openalex.org/W1525851782","https://openalex.org/W1546085053","https://openalex.org/W1834835434","https://openalex.org/W1949194567","https://openalex.org/W1965370740","https://openalex.org/W1973767497","https://openalex.org/W2004295816","https://openalex.org/W2014881369","https://openalex.org/W2017187984","https://openalex.org/W2032211985","https://openalex.org/W2038840577","https://openalex.org/W2043058822","https://openalex.org/W2050573392","https://openalex.org/W2051165598","https://openalex.org/W2070645893","https://openalex.org/W2079398727","https://openalex.org/W2086101743","https://openalex.org/W2092437923","https://openalex.org/W2096024381","https://openalex.org/W2100614336","https://openalex.org/W2101055151","https://openalex.org/W2106543129","https://openalex.org/W2115907364","https://openalex.org/W2124026197","https://openalex.org/W2141674733","https://openalex.org/W2144096834","https://openalex.org/W2149528253","https://openalex.org/W2149576348","https://openalex.org/W2149662085","https://openalex.org/W2154196978","https://openalex.org/W2154748904","https://openalex.org/W2156725040","https://openalex.org/W2160766792","https://openalex.org/W2161277727","https://openalex.org/W2162044478","https://openalex.org/W2168254162","https://openalex.org/W2221435828","https://openalex.org/W4248872320"],"related_works":["https://openalex.org/W2052207423","https://openalex.org/W4298348341","https://openalex.org/W2111281816","https://openalex.org/W2762842128","https://openalex.org/W3170613345","https://openalex.org/W2793233777","https://openalex.org/W2562473065","https://openalex.org/W2334227116","https://openalex.org/W1982833807"],"abstract_inverted_index":{"BI":[0,47,118,129,155],"882370":[1,48,119,130,156],"is":[2],"a":[3,183],"highly":[4],"potent":[5],"and":[6,60,63,140,169,207,233,237],"selective":[7],"RAF":[8],"inhibitor":[9],"that":[10,218],"binds":[11],"to":[12,79,189],"the":[13,18,103,212],"DFG-out":[14],"(inactive)":[15],"conformation":[16],"of":[17,25,57,148,167,198,202,214],"BRAF":[19,227],"kinase.":[20],"The":[21],"compound":[22],"inhibited":[23],"proliferation":[24],"human":[26],"BRAF-mutant":[27,58],"melanoma":[28],"cells":[29,40],"with":[30,73,95,100,133,154,225],"100\u00d7":[31],"higher":[32],"potency":[33],"(1-10":[34],"nmol/L)":[35],"than":[36],"vemurafenib,":[37,74],"whereas":[38],"wild-type":[39],"were":[41,92,173],"not":[42,110,143,158],"affected":[43],"at":[44,64],"1,000":[45],"nmol/L.":[46],"administered":[49],"orally":[50],"was":[51,142],"efficacious":[52],"in":[53,83,114,131,136,175,186,200,230],"multiple":[54],"mouse":[55],"models":[56],"melanomas":[59],"colorectal":[61],"carcinomas,":[62],"25":[65],"mg/kg":[66,191],"twice":[67],"daily":[68,192],"showed":[69],"superior":[70],"efficacy":[71,113],"compared":[72,224],"dabrafenib,":[75],"or":[76,164],"trametinib":[77,134],"(dosed":[78],"provide":[80,219],"exposures":[81],"reached":[82],"patients).":[84],"To":[85],"model":[86],"drug":[87],"resistance,":[88],"A375":[89],"melanoma-bearing":[90],"mice":[91,152],"initially":[93],"treated":[94,153],"vemurafenib;":[96],"all":[97],"tumors":[98],"responded":[99],"regression,":[101],"but":[102],"majority":[104],"subsequently":[105],"resumed":[106],"growth.":[107],"Trametinib":[108],"did":[109,157],"show":[111,159],"any":[112,160],"this":[115],"progressing":[116],"population.":[117],"induced":[120],"tumor":[121],"regression;":[122],"however,":[123],"resistance":[124,141],"developed":[125],"within":[126],"3":[127],"weeks.":[128],"combination":[132],"resulted":[135],"more":[137,231],"pronounced":[138,232],"regressions,":[139],"observed":[144,174],"during":[145],"5":[146],"weeks":[147],"second-line":[149],"therapy.":[150],"Importantly,":[151],"body":[161],"weight":[162],"loss":[163],"clinical":[165,203],"signs":[166],"intolerability,":[168],"no":[170],"pathologic":[171],"changes":[172],"several":[176],"major":[177],"organs":[178],"investigated,":[179],"including":[180],"skin.":[181],"Furthermore,":[182],"pilot":[184],"study":[185],"rats":[187],"(up":[188],"60":[190],"for":[193],"2":[194],"weeks)":[195],"indicated":[196],"lack":[197],"toxicity":[199],"terms":[201],"chemistry,":[204],"hematology,":[205],"pathology,":[206],"toxicogenomics.":[208],"Our":[209],"results":[210],"indicate":[211],"feasibility":[213],"developing":[215],"novel":[216],"compounds":[217],"an":[220],"improved":[221,239],"therapeutic":[222],"window":[223],"first-generation":[226],"inhibitors,":[228],"resulting":[229],"long-lasting":[234],"pathway":[235],"suppression":[236],"thus":[238],"efficacy.":[240]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2285196165","counts_by_year":[{"year":2026,"cited_by_count":12},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":12},{"year":2023,"cited_by_count":12},{"year":2022,"cited_by_count":14},{"year":2021,"cited_by_count":12},{"year":2020,"cited_by_count":13},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":2}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
